112
Participants
Start Date
December 31, 2007
Primary Completion Date
July 31, 2013
Study Completion Date
February 28, 2014
Docetaxel/Carboplatin/Bevacizumab/Erlotinib
"Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."
Docetaxel/Carboplatin
"Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."
Center for Cancer and Blood Disorders, Bethesda
Peninsula Cancer Institute, Newport News
Cancer Care of Western North Carolina, Asheville
Wellstar Cancer Research, Marietta
Northeast Georgia Medical Center, Gainesville
Medical Oncology Associates of Augusta, Augusta
Gulfcoast Oncology Associates, St. Petersburg
Florida Cancer Specialists, Fort Myers
Northeast Alabama Medical Center, Anniston
Tennessee Oncology, PLLC, Nashville
Associates in Hematology Oncology, Chattanooga
Chattanooga Oncology Hematology Associates, Chattanooga
Jackson Oncology Associates, Jackson
Baptist Hospital East, Louisville
Norton Cancer Institute, Louisville
Oncology Hematology Care, Cincinnati
Providence Medical Group, Terre Haute
RHHP/Hope Cancer Center, Terre Haute
St. Louis Cancer Care, Chesterfield
Nebraska Methodist Cancer Center, Omaha
Hematology Oncology Clinic, LLP, Baton Rouge
Hematology Oncology Life Center, Alexandria
Northeast Arkansas Clinic, Jonesboro
New Mexico Oncology Hematology Consultants, Albuquerque
Portsmouth Regional Hospital, Portsmouth
Hematology Oncology Associates of Northern NJ, Morristown
Collaborators (2)
Genentech, Inc.
INDUSTRY
Sanofi
INDUSTRY
SCRI Development Innovations, LLC
OTHER